This study is testing a new nasal spray vaccine called MPV/S-2P for COVID-19. The trial is for adults aged 18-64 who have already had their primary COVID-19 shots and at least one booster. The vaccine will be given through the nose and aims to check if it's safe and how well it works. "Immunogenicity" means the ability of the vaccine to trigger an immune response. "Reactogenicity" is how much a vaccine causes expected side effects like mild fever or soreness.
- The study will have 60 participants and last for several weeks.
- Participants must be in good health and not pregnant.
- They cannot have had a COVID-19 vaccine or infection in the last 16 weeks.
Those in the study must attend all visits, follow specific health guidelines, and agree to wear masks after getting the vaccine. If you want to participate, remember you can’t be pregnant, need to be healthy, and must have had previous COVID-19 vaccines. The trial will help understand the safety of this new nasal spray vaccine.